Abstract
Gene silencing associated with aberrant methylation of promoter region CpG islands is one mechanism in which tumor suppressor genes are inactivated in human cancers. Recently, we identified a novel gene, Target of Methylation-associated Silencing-1 (TMS1) (also called ASC), which is aberrantly methylated and silenced in human breast cancers. To further investigate the mechanism of TMS1 silencing, we defined the transcription initiation site and detailed the DNA methylation pattern of the TMS1 CpG island in normal breast epithelial cells, breast cancer cell lines, and primary tumors. We find that in normal cells, the TMS1 CpG island lies within a 1.2 kb unmethylated domain, the 5′ boundary of which is in close proximity to the transcription initiation site. In breast cancer cell lines, this boundary appeared to be unstable in that methylation tended to accumulate in the 5′ end of the CpG island relative to normal epithelial cells. In contrast, the 3′ methylation boundary remained intact. Gene silencing was not correlated with the methylation of specific CpG sites nor the inability to transactivate the TMS1 promoter, but was correlated with the percentage of alleles in the population exhibiting dense methylation across the entire CpG island. Using 5-aza-deoxycytidine to reactivate TMS1 in methylated and silent cell lines, and a cassette methylation strategy to determine the impact of methylation on different parts of the promoter, we find that demethylation of a small region immediately surrounding the transcription start site is critical to TMS1 expression. Our data support the idea that gene silencing and dense methylation are tightly coupled events that affect individual chromosomal copies of TMS1 in an all-or-none manner. The transition to this stably repressed state may be facilitated by spreading of methylation into the proximal promoter and direct effects of methylation on TMS1 transcription.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baylin SB, Herman JG, Graff JR, Vertino PM and Issa JP . (1998). Adv. Cancer Res., 72, 141–196.
Bender CM, Gonzalgo ML, Gonzales FA, Nguyen CT, Robertson KD and Jones PA . (1999). Mol. Cell. Biol., 19, 6690–6698.
Bird A . (2002). Genes Dev., 16, 6–21.
Bird AP . (1986). Nature, 321, 209–213.
Bird AP and Wolffe AP . (1999). Cell, 99, 451–454.
Cameron EE, Baylin SB and Herman JG . (1999). Blood, 94, 2445–2451.
Campanero MR, Armstrong MI and Flemington EK . (2000). Proc. Natl. Acad. Sci. USA, 97, 6481–6486.
Chomczynski P and Sacchi N . (1987). Anal. Biochem., 162, 156–159.
Conway KE, McConnell BB, Bowring CE, Donald CD, Warren ST and Vertino PM . (2000). Cancer. Res., 60, 6236–6242.
Curradi M, Izzo A, Badaracco G and Landsberger N . (2002). Mol. Cell. Biol., 22, 3157–3173.
Dammann R, Yang G and Pfeifer GP . (2001). Cancer Res., 61, 3105–3109.
Danam RP, Qian XC, Howell SR and Brent TP . (1999). Mol. Carcinogen., 24, 85–89.
Di Fiore B, Palena A, Felsani A, Palitti F, Caruso M and Lavia P . (1999). Nucleic Acids Res., 27, 2852–2859.
Eden S and Cedar H . (1994). Curr. Opin. Genet. Dev., 4, 255–259.
Feng Q, Cao R, Xia L, Erdjument-Bromage H, Tempst P and Zhang Y . (2002). Mol. Cell. Biol., 22, 536–546.
Ferguson AT, Vertino PM, Spitzner JR, Baylin SB, Muller MT and Davidson NE . (1997). J. Biol. Chem., 272, 32260–32266.
Gonzalgo ML, Hayashida T, Bender CM, Pao MM, Tsai YC, Gonzales FA, Nguyen HD, Nguyen TT and Jones PA . (1998). Cancer Res., 58, 1245–1252.
Han L, Lin IG and Hsieh CL . (2001). Mol. Cell. Biol., 21, 3416–3424.
Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB . (1996). Proc. Natl. Acad. Sci. USA, 93, 9821–9826.
Hsieh CL . (1994). Mol. Cell. Biol., 14, 5487–5494.
Ingvarsson S . (1999). Semin. Cancer Biol., 9, 277–288.
Jones PA and Laird PW . (1999). Nat. Genet., 21, 163–167.
Kass SU, Goddard JP and Adams RL . (1993). Biochem. Soc. Trans., 21, 9S.
Kass SU, Landsberger N and Wolffe AP . (1997). Curr. Biol., 7, 157–165.
Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, Choon A, Reznikoff CR, Bova GS, Friedl A and Jarrard DF . (2000). Cancer Res., 60, 3623–3630.
Krop IE, Sgroi D, Porter DA, Lunetta KL, LeVangie R, Seth P, Kaelin CM, Rhei E, Bosenberg M, Schnitt S, Marks JR, Pagon Z, Belina D, Razumovic J and Polyak K . (2001). Proc. Natl. Acad. Sci. USA, 98, 9796–9801.
Mann JR, Szabo PE, Reed MR and Singer-Sam J . (2000). Crit. Rev. Eukaryot. Gene. Expr., 10, 241–257.
Martin AM and Weber BL . (2000). J. Natl. Cancer Inst., 92, 1126–1135.
Masumoto J, Taniguchi S, Ayukawa K, Sarvotham H, Kishino T, Niikawa N, Hidaka E, Katsuyama T, Higuchi T and Sagara J . (1999). J. Biol. Chem., 274, 33835–33838.
McConnell BB and Vertino PM . (2000). Cancer Res., 60, 6243–6247.
Schmitt AO, Specht T, Beckmann G, Dahl E, Pilarsky CP, Hinzmann B and Rosenthal A . (1999). Nucleic Acids Res., 27, 4251–4260.
Song JZ, Stirzaker C, Harrison J, Melki JR and Clark SJ . (2002). Oncogene, 21, 1048–1061.
Srinivasula SM, Poyet JL, Razmara M, Datta P, Zhang Z and Alnemri ES . (2002). J. Biol. Chem., 277, 21119–21122.
Stimson KM and Vertino PM . (2002). J. Biol. Chem., 277, 4951–4958.
van ’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R and Friend SH . (2002). Nature, 415, 530–536.
Wade PA . (2001). Oncogene, 20, 3166–3173.
Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F and Wolffe AP . (1999). Nat. Genet., 23, 62–66.
Wang L, Manji G, Grenier JM, Al-Garawi A, Merriam S, Lora JM, Geddes BJ, Briskin M, DiStefano PS and Bertin J . (2002). J. Biol. Chem., 17, 17.
Yang X, Yan L and Davidson NE . (2001). Endocr. Relat. Cancer, 8, 115–127.
Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A and Reinberg D . (1999). Genes Dev., 13, 1924–1935.
Acknowledgements
We thank Annalisa Stone for excellent technical assistance and Dr. Paraskevi Giannakakou for her critical review of the manuscript. This work was supported in part by PHS Grant 1RO1 CA77337 from the National Cancer Institute and funds from the Avon Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Levine, J., Stimson-Crider, K. & Vertino, P. Effects of methylation on expression of TMS1/ASC in human breast cancer cells. Oncogene 22, 3475–3488 (2003). https://doi.org/10.1038/sj.onc.1206430
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206430
Keywords
This article is cited by
-
Comprehensive review of ASC structure and function in immune homeostasis and disease
Molecular Biology Reports (2020)
-
Culturing conditions highly affect DNA methylation and gene expression levels in MCF7 breast cancer cell line
In Vitro Cellular & Developmental Biology - Animal (2018)
-
S100A7 has an oncogenic role in oral squamous cell carcinoma by activating p38/MAPK and RAB2A signaling pathway
Cancer Gene Therapy (2016)
-
NLR-regulated pathways in cancer: opportunities and obstacles for therapeutic interventions
Cellular and Molecular Life Sciences (2016)
-
Pathways of Tumor development and progression in Drug-induced Nonmelanoma Skin Cancer: a New Hope or the Next Great Confusion?
Wiener Medizinische Wochenschrift (2014)